Intercell's S. pneumoniae vacc enters Ph I testing

Austrian vaccine maker Intercell AG has initiated a Phase I trial of its vaccine candidate IC47 to prevent disease caused by the bacterium  Streptococcus pneumoniae.

The agent is a recombinant subunit vaccine consisting of three conserved  surface proteins from S. pneumoniae. Two of these proteins were  discovered using Intercell's proprietary Antigen Identification Program,  while the third was in-licensed from the US Centers for Disease Control  and Prevention.

This Phase I trial is a first-in-man study with a focus on obtaining  safety and immunogenicity data in a small population of healthy adults.  32 subjects will be enrolled in this open-label study. Two different  vaccine concentrations, either with or without the addition of an  adjuvant, will be tested.